Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Ann Vasc Surg. 2015 Nov 23;31:124–133. doi: 10.1016/j.avsg.2015.08.017

Pre-operative predictors of 30-day mortality and prolonged length of stay after above-knee amputation

Eric S Wise 1,*, William G McMaster Jr 1, Kelly Williamson 2, Justine E Wergin 2, Kyle M Hocking 1,3, Colleen M Brophy 4,1
PMCID: PMC4744093  NIHMSID: NIHMS740454  PMID: 26616501

Abstract

Background

The above-knee amputation (AKA) is an operation of last resort with high post-operative morbidity and mortality. This study identifies pre-operative risk factors predictive of both 30-day mortality and extended length of stay (LOS) in AKA patients.

Materials and Methods

Two hundred and ninety-five AKA patients from 2004-2013 from a single institution were retrospectively reviewed using a de-identified electronic medical record. Rationally selected factors potentially influencing 30-day mortality and LOS were chosen, including demographics, etiologies, vascular surgical history, lifestyle factors, comorbidities and laboratory values. Variables trending with one of the endpoints on bivariate analysis (P ≤ .10) were entered into multivariate forward stepwise regression models to determine independence as a risk factor (P ≤ .05). Subgroup analysis of AKA patients without a traumatic, burn or malignant etiology was similarly conducted.

Results

Within the 295 patient cohort, 60% of patients were male, 18% were African-American, mean age was 58 years old and mean body-mass index was 28 kg/m2. The 30-day mortality rate was 9%, and mean post-operative LOS of discharged patients was 9.3 days. Upon logistic regression, thrombocytopenia (platelet count < 250 ×106/mL; P < .001, odds ratio 6.1) and pre-operative septic shock (P = .02, odds ratio 5.1) were identified as independent risk factors for 30-day mortality. Upon linear regression, burn etiology (P < .001, B = 15.8 days), leukocytosis (white blood cell count < 12 ×106/mL; P < .001, B = 6.2 days) and guillotine amputation (P < .001, B = 7.6 days) were independently associated with prolonged LOS. Excluding patients with AKAs due to trauma, burn or malignancy, only thrombocytopenia (platelet count < 250 ×106/mL; P < .001, odds ratio 10.2) and leukocytosis (white blood cell count > 12 ×106/mL; P = .01, B = 5.2 days) were independent risk factors for in-hospital mortality and prolonged LOS, respectively.

Conclusions

Pre-operative septic shock and thrombocytopenia are independent risk factors for 30-day mortality after AKA, while burn etiology, leukocytosis and guillotine amputation contribute to prolonged LOS. Awareness of these risk factors may help enhance both pre-operative decision-making and expectations of the hospital admission.

Keywords: outcomes, amputation, above-knee amputation, peripheral arterial disease, diabetic neuropathy, mortality, length of stay

INTRODUCTION

Over 100,000 major lower extremity amputations, including below-knee amputations (BKA) and above-knee amputations (AKA), are performed annually in the United States.1, 2 The one-year survival rate for these patients is estimated to be 69-78%, lower in the cohort requiring AKA.3, 4 Relative to BKA patients, AKA patients are less likely to regain mobility and functional independence post-operatively due to loss of the knee joint.5 AKA recipients are frequently poor surgical candidates.5 The care of these patients extends well beyond their inpatient stay, as they require aggressive rehabilitation, assessment for prosthesis, nutritional optimization and significant social work needs. The care of these patients is extremely costly, and a post-operative course wrought with complications and a poor quality of life is not uncommon.1, 4-7 In cases of chronic ischemia, a contributor to the etiology of the majority of AKA operations, even revascularization attempts with a low chance of success are recommended for limb salvage therapy antecedent to AKA.8

Identification of patients who are at risk for perioperative mortality or prone to extended hospitalizations presents a challenge. In 2012 and 2013, the American College of Surgeons National Surgical Quality Improvement Program database was retrospectively examined, finding that not only was the 30-day mortality rate of AKA patients double that of the BKA (12.8% vs. 6.5%), but mortalities could be partially predicted on the basis of a panel of pre-operative variables.9, 10 Hospital length of stay (LOS) is another important outcome measure. Among diabetic inpatients with peripheral arterial disease, those who required a major amputation experienced a far more costly clinical course than those who required other interventions including bypass, percutaneous transluminal angioplasty, minor amputation or debridement.11 This finding was chiefly attributed to the profoundly long hospital stays these patients often require.11 The purpose of our study was to examine and evaluate simple, rationally selected pre-operative variables that may portend the important outcome measures of 30-day mortality or prolonged LOS among our patient population, using our institutional cohort of AKA patients.

MATERIALS AND METHODS

This was a single-institution, retrospective analysis of risk factors for 30-day mortality and prolonged LOS after AKA from 2004-2013. Patients who underwent AKA were determined via the Vanderbilt University Synthetic Derivative, a database that mirrors the electronic medical record after removal of all patient identifiers.12 As there was no identifying information available, this study was approved by the Vanderbilt University Institutional Review Board with waiving of informed consent. Using a search algorithm for patients with an associated Current Procedural Terminology code for AKA (27590, 27591 or 27592), 514 patients who underwent AKA were found. Patients were excluded if they did not have their operation between 2004-2013 (182 patients) or did not have sufficient data available in the medical record (37 patients). Ultimately, 295 patients were included for analysis.

Included patients were reviewed for demographics and rationally selected patient characteristics. Body-mass index (BMI) and laboratory values were taken as the last documented value before surgery, though laboratory values > 7 days prior to surgery were excluded. Comorbidities were attributed by the presence of an associated ICD.9 code pre-operatively,13 with chart review confirmation.14 For simplicity, only the presence or absence of a comorbidity was considered. Selected variables are reported in Table I. All continuous patient variables were dichotomized prior to statistical analysis, using clinical sense and prior reports to approximate a useful and appropriate cut-off value (e.g. white blood cell [WBC] count cut-off at 12 × 106/mL). Primary endpoints were 30-day mortality and LOS, defined as the difference from the day of the index operation to discharge (home, rehabilitation or assisted living facility). All data was managed using the Vanderbilt Research Electronic Data Capture (REDCap) platform.15 Subgroup analysis was also performed on 206 patients, excluding those with etiologies related to trauma, burn or malignancy.13

Table I.

AKA recipient baseline characteristics, all patients

Pre-operative Variable n Number (%), or Mean
± Standard Deviation
Demographics:
Male Gender 295 176 (60)
African-American 295 52 (18)
Age (yrs) 291 58 ± 18
Body-Mass Index (kg/m2) 199 28 ± 9
Etiology:
Trauma 295 43 (15)
Burn 295 13 (4)
Malignancy 295 33 (11)
Vascular History:
Prior Revascularization Attempt 292 90 (31)
Prior Amputation (any), AKA side 293 83 (28)
Prior BKA-Level Amputation, AKA side 293 61 (21)
Prior Amputation (any level), contralateral side 295 35 (12)
Prior Contralateral BKA/AKA 295 29 (10)
Lifestyle Factors:
Smoking Status:
Previous Smoker 277 71 (26)
Current Smoker 277 103 (37)
Functional Status:
Fully Independent 274 163 (59)
Partially Dependent 274 52 (19)
Dependent 274 59 (22)
Residence:
Assisted Living 275 38 (14)
Non-Assisted Living 275 237 (86)
Comorbidities:
Ischemic Heart Disease 295 106 (36)
Congestive Heart Failure 295 73 (25)
Chronic Pulmonary Disease 295 40 (14)
Diabetes Mellitus 295 109 (37)
Peripheral Arterial Disease 295 117 (40)
Septic Shock 295 11 (4)
Dialysis Use or Dependence 295 30 (10)
Laboratory Values:
Blood Urea Nitrogen (mg/dL) 213 21 ± 14
Platelets (106/mL ) 260 286 ± 141
International Normalized Ratio 249 1.3 ± 0.6
White Blood Cells (106/mL) 255 12.1 ± 6.7
Albumin (g/dL) 128 2.9 ± 0.8
Packed Cell Volume (%) 276 31.8 ± 6.0
Other Factors:
Guillotine Amputation 288 53 (18)
Steroid Use 295 17 (6)
Outcome Measures:
30-day Mortality 295 26 (9)
LOS, Discharged Patients (days) 269 9.3 ± 12.9

n- number of patients considered in analysis; AKA- above-knee amputation; BKA- below-knee amputation; LOS, length of stay

Bivariate analysis of all variables was conducted to screen for those factors associated with 30-day mortality (via Pearson chi-squared test) and LOS (via bivariate linear regression analysis). Factors that trended with 30-day mortality or LOS (P < .10) were included in logistic and linear multivariate stepwise regression models, respectively. Variables significant upon multivariate analysis were deemed independent predictors of the endpoints, at a level of statistical significance of P ≤ .05. As all variables included in multivariate analyses had a variance inflation factor < 1.8, collinearity was not statistically considered. Albumin level was excluded from multivariate models due to a prohibitively large number of missing values. Measures of central tendency were reported as mean ± standard deviation. Statistical analysis was performed with JMP Pro 11 (Cary, NC) and GraphPad Prism (La Jolla, CA).

RESULTS

The cohort included 295 patients who underwent AKA from 2004-2013. Patient demographics and clinical characteristics for these patients are presented in Table I. Sixty percent (176/295) of the patients were male, 18% (52/295) were African-American, the mean age at operation was 58 ± 18 years and the mean body-mass index (BMI) was 28 ± 9 kg/m2. Thirty-one percent (90/292) of the patients had a prior revascularization attempt on the amputated extremity. Consistent with reported estimates,4, 5 9% of patients were 30-day mortalities (26/295), and the mean LOS, considered only for the 269 patients who survived to discharge, was 9.3 ± 12.9 days.

Bivariate Pearson chi-squared analysis was conducted for those factors which exhibited a trend towards increased risk of mortality, at a level of evidence P ≤ .10. The results of this analysis are presented in Table II. Gender, race, age and BMI were not associated with 30-day mortality. Traumatic etiology (P = .06; odds ratio [OR] 2.4) and malignant etiology (P = .06; OR 0.13) trended toward an increased and decreased risk of 30-day mortality, respectively. Prior vascular surgical history was not associated with 30-day mortality. Several lifestyle factors did demonstrate a trend, including current smoker (P = .02, OR 0.28), fully independent functional status (P = .08, OR 2.5) and partially dependent functional status (P = .07; OR 0.19). Among comorbidities, congestive heart failure (P = .09; OR 2.0) and septic shock trended with 30-day mortality (P = .001; OR 6.8). Laboratory measurements associated with 30-day mortality included thrombocytopenia (platelets < 250 ×106/mL, P < .001; OR 6.4), elevated international normalized ratio (INR; INR > 1.3, P = .006; OR 3.4) and hypoalbuminemia (albumin < 2.2, P = .005; OR 4.5). Guillotine amputation (P = .004; OR 3.4) and pre-operative steroid use (P = .03; OR 3.6) were also associated with 30-day mortality.

Table II.

Bivariate analysis of pre-operative factors associated with 30-day mortality, all patients

Pre-operative Variable* Mortality Rate
(with variable)
Mortality Rate
(without
variable)
P OR (95% CI)
Demographics:
Male Gender 16/176 10/119 .84 1.1 (0.48, 2.5)
African-American 3/52 23/243 .39 0.59 (0.17, 2.0)
Age > 60 yrs 16/147 10/144 .24 1.6 (0.72, 3.7)
Body-Mass Index > 27.5
kg/m2
7/85 9/114 .93 1.0 (0.37, 2.9)
Etiology:
Trauma 7/43 19/252 .06 2.4 (0.94, 6.1)
Burn 1/13 25/282 .88 0.86 (0.11, 6.9)
Malignancy 0/33 26/262 .06 0.13 (0.008, 2.2)
Vascular History:
Prior Revascularization
Attempt
8/90 18/202 .99 1.0 (0.42, 2.4)
Prior Amputation (any),
AKA side
6/83 19/210 .92 0.78 (0.30, 2.0)
Prior BKA-Level
Amputation, AKA side
4/61 21/232 .53 0.71 (0.23, 2.1)
Prior Amputation (any
level), contralateral side
5/35 21/260 .22 1.9 (0.67, 5.4)
Prior Contralateral
BKA/AKA
4/29 22/266 .32 1.8 (0.56, 5.6)
Lifestyle Factors:
Smoking Status:
Previous Smoker 9/71 17/206 .27 1.6 (0.68, 3.8)
Current Smoker 4/103 22/174 .02 0.28 (0.09, 0.83)
Functional Status:
Fully Independent 17/163 5/111 .08 2.5 (0.88, 6.9)
Partially Dependent 1/52 21/222 .07 0.19 (0.03, 1.4)
Dependent 4/59 18/215 .69 0.80 (0.26, 2.5)
Residence:
Assisted Living 1/38 19/237 .24 0.31 (0.04, 2.4)
Non-Assisted Living 19/237 1/38 .24 3.2 (0.42, 24.8)
Comorbidities:
Ischemic Heart Disease 10/106 16/189 .78 1.1 (0.49, 2.6)
Congestive Heart Failure 10/73 16/222 .09 2.0 (0.88, 4.7)
Chronic Pulmonary Disease 3/40 23/255 .75 0.82 (0.23, 2.9)
Diabetes Mellitus 8/109 18/186 .49 0.74 (0.31, 1.8)
Peripheral Arterial Disease 10/117 16/178 .90 0.95 (0.41, 2.2)
Septic Shock 4/11 22/284 .001 6.8 (1.8, 25.1)
Dialysis Use or Dependence 4/30 22/265 .36 1.7 (.54, 5.3)
Laboratory Values:
Blood Urea Nitrogen > 30
mg/dL
7/52 15/161 .39 1.5 (0.58, 3.9)
Platelets < 250 ×106/mL 20/110 5/150 <.001 6.4 (2.3, 17.8)
International Normalized
Ratio > 1.3
17/111 7/139 .006 3.4 (1.4, 8.6)
White Blood Cells >12
×106/mL
12/93 13/162 .21 1.7 (0.75, 3.9)
Albumin < 2.2 g/dL 8/31 7/97 .005 4.5 (1.5, 13.6)
Packed Cell Volume < 31% 14/115 11/161 .12 1.9 (0.82, 4.3)
Other Factors:
Guillotine Amputation 10/53 15/235 .004 3.4 (1.4, 8.1)
Steroid Use 4/17 22/278 .03 3.6 (1.1, 11.9)

n, number of patients considered in analysis; OR, odds ratio; CI, confidence interval

*

Continuous variables have been dichotomized

Bivariate linear regression analysis was used to determine those variables that demonstrated a trend (P ≤ .10) with LOS. The results of this analysis are presented in Table III. Three etiologies trended with LOS, including trauma (P = .05; B = 4.5 days), burn (P < .001; B = 19.4 days) and malignancy (P =.02; B = −5.7 days). Fully independent (P = .007; B = 4.6 days) and partially dependent (P = .03; B = −4.4 days) functional statuses were the only correlated lifestyle factors. Additional factors associated with LOS included leukocytosis (WBC > 12 ×106/mL, P < .001; B = 7.7 days) and guillotine amputation (P < .001; B = 10 days).

Table III.

Bivariate analysis of factors associated with post-operative length of stay, all patients

Pre-operative Variable* n P B (days) 95% CI (days)
Demographics:
Male Gender 269 .93 0.13 −3.0, 3.3
African-American 269 .21 2.6 −1.4, 6.6
Age > 60 yrs 265 .12 −2.5 −5.6, 0.64
Body-Mass Index > 27.5
kg/m2
183 .93 −0.20 −4.5, 4.1
Contribution to
Etiology:
Trauma 269 .05 4.5 0.04, 9.0
Burn 269 <.001 19.4 12.3, 26.5
Malignancy 269 .02 −5.7 −10.3, -0.99
Vascular History:
Prior Revascularization
Attempt
266 .61 −0.88 −4.3, 2.5
Prior Amputation (any),
AKA side
268 .46 1.3 −2.1, 4.7
Prior BKA-Level
Amputation, AKA side
268 .27 2.1 −1.6, 5.9
Prior Amputation (any
level), contralateral side
269 .82 2.3 −2.6, 7.2
Prior Contralateral
BKA/AKA
269 .22 3.3 −2.0, 8.6
Lifestyle Factors:
Smoking Status:
Previous Smoker 257 .60 1.0 −2.7, 4.7
Current Smoker 257 .91 −0.20 −3.5, 3.1
Functional Status:
Fully Independent 252 .007 4.6 1.3, 7.9
Partially Dependent 252 .03 −4.4 −8.4, −0.34
Dependent 252 .24 −2.4 −6.4, 1.6
Residence:
Assisted Living 255 .11 −3.8 −8.3, 0.84
Non-Assisted Living 255 .11 3.8 −0.84, 8.3
Comorbidities:
Ischemic Heart Disease 269 .22 −2.0 −5.3, 1.2
Congestive Heart Failure 295 .20 −2.4 −6.0, 1.2
Chronic Pulmonary
Disease
269 .76 −0.71 −5.2, 3.8
Diabetes Mellitus 269 .34 1.5 −1.6, 4.7
Peripheral Arterial
Disease
269 .27 −1.8 −4.9, 1.4
Septic Shock 269 .68 2.0 −7.6, 11.8
Dialysis Use or
Dependence
269 .74 0.87 04.4, 6.1
Laboratory Values:
Blood Urea Nitrogen > 30
mg/dL
191 .38 1.9 −2.4, 6.2
Platelets < 250 ×106/mL 235 .48 1.3 −2.3, 4.9
International Normalized
Ratio > 1.3
225 .18 2.1 −0.92, 5.0
White Blood Cells >12
×106/mL
230 <.001 7.7 4.1, 11.3
Albumin < 2.2 g/dL 113 .13 4.0 −1.2, 9.1
Packed Cell Volume <
31%
276 .16 2.1 −0.82, 5.0
Other Factors:
Guillotine Amputation 263 <.001 10.0 5.9, 14.1
Steroid Use 269 .96 0.18 −7.0, 7.4

n, number of patients considered in analysis; CI, confidence interval

*

Continuous variables have been dichotomized

Results of the stepwise multivariate regression analyses are presented in Table IV. Independent predictors of 30-day mortality were thrombocytopenia (platelet count < 250 ×106/mL; P < .001, OR 6.1) and pre-operative septic shock (P = .02, OR 5.1). Pre-operative predictors of prolonged LOS were burn etiology (P < .001, B = 15.8 days), leukocytosis (WBC > 12 ×106/mL; P < .001, B = 6.2 days) and guillotine amputation (P < .001, B = 7.6 days). Traumatic and malignant etiologies, and strata of functional status lost significance.

Table IV.

Multivariate analysis for independent association with 30-day mortality and length of stay, all patients

Pre-operative Variable* 30-day mortality Length of Stay
P OR (95% CI) P B (95% CI)(days)
Traumatic Etiology ns ns ns ns
Burn Etiology <.001 15.8 (8.4, 23.2)
Malignant Etiology ns ns ns ns
Current Smoker ns ns
Fully Independent ns ns ns ns
Partially Dependent ns ns ns ns
Congestive Heart Failure ns ns
Septic Shock .02 5.1 (1.2, 20.2)
Platelets < 250 ×106/mL <.001 6.1 (2.3, 19)
INR > 1.3 ns ns
WBC > 12 ×106/mL <.001 6.2 (2.7, 9.7)
Guillotine Amputation ns ns <.001 7.6 (3.3, 12)
Steroid Use ns ns

INR, international normalized ratio; WBC, white blood cells; OR, odds ratio; CI, confidence interval; ns, not significant

*

Continuous variables have been dichotomized;

n = 260, multivariate stepwise logistic regression; constant = 3.5, Chi-square = 21.1, r2 = .13, P < .001;

n = 225 patients, multivariate stepwise linear regression; constant = 5.6 days, r2 = 0.19, F = 17.7, P < .001

A brief contrast between the subgroup and the excluded cohort of patients amputated due to trauma, burn or malignancy is reported in Table V. Notably, the patients within the subgroup had a greater percentage of African-Americans (22% vs. 8%, P = .004), were older (61.9 ± 14.9 years vs. 49.8 ± 20.6 years, P < .001) and had a shorter LOS (8.2 ± 11.9 days vs. 11.8 ± 15.0 days, P = .04). No differences in gender, BMI and mortality rate were noted.

Table V.

Comparison of AKA patient demographics, by class of etiology

Pre-operative Variable* Non-Trauma/Burn/
Malignant subgroup
Trauma/Burn/
Malignant Etiologies
P *
Male Gender 56% (116/206) 67% (60/89) .07
African-American 22% (45/206) 8% (7/89) .004
Age 61.9 ± 14.9 49.8 ± 20.6 <.001
Body-Mass Index
(kg/m2)
28 ± 8 28 ± 10 .70
30-day Mortality 9% (18/206) 9% (8/89) .94
LOS, Discharged
Patients (days)
8.2 ± 11.9 11.8 ± 15.0 .04

LOS, length of stay

*

Categorical variables, expressed as percentages (fractions), were analyzed via Pearson chi-squared test; continuous variables, expressed as mean ± standard deviation, were analyzed using unpaired Student t-test

Results of the subgroup bivariate screen for both 30-day mortality and LOS are reported in Table VI. Pre-operative variables trending with 30-day mortality in this cohort included previous smoker (P = .09, OR 2.4), current smoker (P = .052, OR 0.30), fully independent (P = .04, OR 3.3) and partially independent (P = .10, OR 0.21) functional statuses, septic shock (P < .001, OR 8.7), thrombocytopenia (platelet count < 250 ×106/mL; P < .001, OR 10.3), elevated INR (INR > 1.3; P = .04, OR 3.0), hypoalbuminemia (albumin < 2.2 g/dL; P = .01, OR 4.5), low packed cell volume (packed cell volume < 31%, P = .04, OR 2.8) and guillotine amputation (P = .052, OR 3.2). Those that trended with LOS included African-American race (P = .02, B = 4.9 days), fully independent functional status (P = .07, B = 3.3 days), diabetes mellitus (P = .08, B = 3.0 days) and leukocytosis (WBC > 12 ×106/mL; P < .001, B = 5.2 days). Reported in Table VII, only thrombocytopenia (platelet count < 250 ×106/mL; P < .001, odds ratio 10.2) and leukocytosis (WBC > 12 ×106/mL; P = .01, B = 5.2 days) remained significant risk factors for 30-day mortality and LOS, respectively, on subgroup multivariate analysis.

Table VI.

Bivariate analysis of preoperative factors associated with 30-day mortality and length of stay, subgroup

Pre-operative
Variable*
30-day Mortality Length of Stay
n P OR (95% CI) n P B (95% CI)(days)
Demographics:
Male Gender 206 .57 0.76 (0.29, 2.0) 188 .91 −0.2 (−3.6, 3.2)
African-American 206 .25 0.42 (0.09, 1.9) 188 .02 4.9 (0.92, 8.8)
Age > 60 yrs 206 .18 2.1 (0.70, 6.0) 188 .64 −0.81 (−4.2, 2.6)
Body-Mass Index > 206 .61 0.74 (0.24, 2.3) 138 .83 0.50 (−3.9, 4.9)
27.5 kg/m2
Vascular History:
Prior Revascularization
Attempt
204 .97 0.99 (0.37, 2.7) 186 .72 0.65 (−2.8, 4.1)
Prior Amputation (any),
AKA side
204 .50 0.68 (0.26, 1.8) 187 .27 2.1 (−1.6, 5.7)
Prior BKA-Level 204 .33 0.48 (0.10, 2.2) 187 .14 3.1 (−0.95, 7.2)
Amputation, AKA side
Prior Amputation (any
level), contralateral side
206 .34 1.8 (0.54, 5.8) 188 .64 1.2 (−3.7, 6.0)
Prior Contralateral 206 .49 1.6 (0.42, 6.0) 188 .49 1.9 (−3.5, 7.2)
BKA/AKA
Lifestyle Factors:
Smoking Status:
Previous Smoker 199 .09 2.4 (0.86, 6.4) 182 .27 2.2 (−1.7, 6.1)
Current Smoker 199 .052 0.30 (0.08, 1.1) 182 .12 −2.8 (−6.3, 0.71)
Functional Status:
Fully Independent 193 .04 3.3 (1.0, 10.7) 177 .07 3.3 (−0.3, 6.8)
Partially Dependent 193 .10 0.21 (0.03, 1.6) 177 .12 −3.3 (−7.4, 0.84)
Dependent 193 .42 0.59 (0.16, 2.1) 177 .62 −1.0 (−5.0, 3.0)
Residence:
Assisted Living 195 .17 0.26 (0.03, 2.1) 179 .23 −2.7 (−7.1, 1.7)
Non-Assisted Living 195 .17 3.8 (0.48, 29.6) 179 .23 2.7 (−1.7, 7.1)
Comorbidities:
Ischemic Heart Disease 206 .88 1.1 (0.41, 2.9) 188 .96 −0.08 (−3.5, 3.3)
Congestive Heart
Failure
206 .12 2.1 (0.81, 5.6) 188 .45 −1.4 (−5.0, 2.2)
Chronic Pulmonary
Disease
206 .84 1.1 (0.31, 4.2) 188 .97 −0.09 (−4.8, 4.6)
Diabetes Mellitus 206 .52 0.72 (0.27, 1.9) 188 .08 3.0 (−0.37, 6.3)
Peripheral Arterial
Disease
206 .82 1.1 (0.42, 2.9) 188 .85 0.31 (−3.1, 3.7)
Septic Shock 206 <.001 8.7 (2.2, 34.4) 188 .56 2.9 (−6.7, 12.4)
Dialysis Use or
Dependence
206 .88 1.2 (0.34, 4.6) 188 .39 2.2 (−2.7, 7.0)
Laboratory Values:
Blood Urea Nitrogen >
30 mg/dL
160 .73 1.2 (0.40, 3.7) 144 .38 2.2 (−2.7, 7.0)
Platelets < 250 ×106/mL 180 <.001 10.3 (2.8, 37.6) 163 .51 −1.4 (−5.5, 2.7)
International 185 .04 3.0 (1.0, 8.7) 167 .24 2.2 (−1.4, 5.7)
Normalized Ratio > 1.3
White Blood Cells >12
×106/mL
176 .29 1.7 (0.63, 4.7) 159 <.001 5.2 (1.1, 9.2)
Albumin < 2.2 g/dL 94 .01 4.5 (1.3, 15.8) 82 .96 0.18 (−6.8, 7.1)
Packed Cell Volume <
31%
202 .04 2.8 (1.0, 7.6) 184 .53 1.1 (−2.4, 4.7)
Other Factors:
Guillotine Amputation 200 .052 3.2 (0.94, 11.0) 183 .14 4.6 (−1.5, 10.7)
Steroid Use 206 .11 2.9 (0.74, 11.6) 188 .68 1.5 (−5.4, 8.3)

n, number of patients considered in analysis; OR, odds ratio; CI, confidence interval; AKA, above-knee amputation; BKA, below-knee amputation

*

Continuous variables have been dichotomized

Table VII.

Multivariate analysis for independent association with 30-day mortality and length of stay, subgroup

Pre-operative Variable* 30-day mortality Length of Stay
P OR (95% CI) P (95% CI)(days)
African-American race - - ns ns
Previous Smoker ns ns - -
Current Smoker ns ns - -
Fully Independent ns ns ns ns
Partially Dependent ns ns - -
Diabetes Mellitus - - ns ns
Septic Shock ns ns - -
Platelets < 250 ×106/mL <.001 10.2 (2.9, 45.9) - -
INR > 1.3 ns ns - -
WBC > 12 ×106/mL - - .01 5.2 (1.1, 9.3)
PCV < 31% ns ns - -
Guillotine amputation ns ns - -

INR, international normalized ratio; WBC, white blood cells; PCV, packed cell volume; OR, odds ratio; CI, confidence interval; ns, not significant

*

Continuous variables have been dichotomized;

n = 180, multivariate stepwise logistic regression; constant = 3.6, Chi-square = 17.0, R2 = .10, P < .001;

n = 159 patients, multivariate stepwise linear regression; constant = 5.6 days, R2 = 0.04, F = 6.2, P = .01

DISCUSSION

Patients undergoing an AKA have a high 30-day mortality, which has been reported between 9% and 31%.4, 7, 9, 10, 16-18 Patients who are unlikely to survive past thirty days would benefit from non-operative management rather than undergo the AKA, which is often associated with significant deleterious psychological and physical sequelae.5, 6, 9, 10 Moreover, even if patients with a poor prognosis pre-operatively do survive to discharge, they are unlikely to have a successful functional outcome.6 Conversely, patients who have a low risk for 30-day mortality are more likely to have a meaningful and more independent functional status.19, 20

Independent risk factors for 30-day mortality among all patients included thrombocytopenia and pre-operative septic shock, providing the first validation of the novel findings of Nelson and colleagues; only thrombocytopenia after exclusion of patients with traumatic, burn and malignant etiologies.9 Thrombocytopenia is a risk marker of infection and septic shock. Its development is thought to be multifactorial, due to decreased platelet production, increased platelet consumption and platelet sequestration in severely ill patients.21, 22 Among patients in the intensive care setting for all causes, thrombocytopenia (or a dramatic drop in platelet count) is also validated independent marker for mortality.22 In septic shock patients, the AKA operation is ostensibly required for source control. To this effect, the concurrent bivariate association of guillotine amputations with 30-day mortality was found as well; unlike thrombocytopenia, guillotine amputation was not sufficiently distinct from septic shock to maintain independent association, however. Our data confirms the association of septic shock with 30-day mortality, though these patients are also at risk for early amputation failure, wound complications and non-wound complications during the remainder of their inpatient stay.23

Our bivariate analysis suggested additional potential risk factors, though we lacked power to detect independent association on multivariate analysis. Bivariate analysis revealed that being an active smoker was protective toward 30-day mortality, a seemingly counterintuitive result but consistent with findings from both the Veterans Administration population and the private sector.10, 24 Karam et al. postulated this was due to the notion that active smoking status may indicate the patient is still healthy enough to do so.10 Additionally, albumin level as a surrogate for poor nutritional status was a strong risk factor for 30-day mortality (P = .005; OR 4.5) on bivariate analysis. Though excluded from multivariate models due to an abundance of missing values, the serum albumin level as a surrogate for poor nutritional status is regarded as a strong predictor of post-operative mortality following myriad operations.25

Though our data did demonstrate the association of two pre-operative variables with 30-day mortality, there were several notable negative findings. As an example, it was anticipated that patients with poor functional status pre-operatively would have a greater 30-day mortality rate.18 Patients with a poor functional status, as quantified by the Activities of Daily Living Long Form Score,26 have a poor post-operative trajectory, with a very slow recovery to their baseline functional status. However, full independence was associated with increased risk of 30-day mortality on bivariate analysis, possibly due to association with etiologies carrying a high mortality, though this trend was lost upon multivariate analysis.

Along with 30-day mortality, we identified pre-operative risk factors for prolonged LOS following AKA. LOS was determined for patients who were not 30-day mortalities. As an endpoint, LOS is important due to its association with increased costs, morbidities as well risk of nosocomial sequelae including infection and delirium, complications exacerbated in AKA patients.27, 28 Median post-operative LOS for AKA patients has been reported at 5 days, similar to patients who undergo BKA or transmetatarsal amputation.23 Our median LOS was 6 days, with a mean of 9.3 days. Upon multivariate analysis, our study had the power to detect the association of burn etiology with LOS. Expectedly, while burn patients survive to discharge, they experience a prolonged post-operative inpatient stay for wound management, debridement and skin grafting procedures as well as suitable recovery of function prior to discharge to rehabilitation. An AKA for burn also represents an unplanned, urgent procedure. Non-elective AKAs are established independent risk factors for death, amputation failure and readmission; our data infers it may also be a risk factor for prolonged LOS.10, 23, 29 In contrast, patients with a planned AKA due to malignancy likely had infrastructure in place to facilitate prompt discharge.

We further report the association between leukocytosis and guillotine amputation with prolonged LOS, only the former, however, in the subgroup. Leukocytosis is a proxy for concomitant infection or sepsis, while the need for guillotine amputation represents a more acute, urgent pre-operative disease requiring wound care and eventual formal closure. Fully independent functional status was also associated with prolonged post-operative stay, though only upon bivariate analysis. We postulate this is due to the needed time necessary to facilitate an appropriate disposition, requiring the ab initio establishment of appropriate rehabilitation and assisted living resources, though this may reflect a degree of collinearity with burn patients who were previously fully functional.

The failure to exclude patients with traumatic, burn and malignant etiologies represents a legitimate criticism of existing outcomes data, as analysis of this cohort together with amputees due to chronic ischemic disease or complications thereof may be faulty or impractical.9, 10 Other studies selectively excluded this cohort to provide an emphasis on those patients with primarily vascular disease and diabetic neuropathy.5, 7, 13, 16 In our study, we report both a procedure-level analysis considering all patients who underwent AKA, and a dedicated subgroup analysis with selective exclusion to allow our data an adequate comparison with existing literature.

In summary, our study affirmed the reported independent association of septic shock and thrombocytopenia with 30-day mortality after AKA and reported three novel risk factors, burn etiology, leukocytosis and guillotine amputation, contributing to prolonged LOS. We were not able to detect a significant association with other reported risk factors, including age, race and select comorbidities and laboratory values, among others.7, 9, 10, 17 Inability to detect these associations may be partially a function of sample size, one of the primary limitations of our study. Our 295 patient cohort is commensurate with multiple other studies of patients with major lower extremity amputation, however, our 30-day mortality rate of 9% limits the ability to detect differences among the survivors and the mortalities. Additionally, the study data was retrospectively collected from a prospectively maintained database, leading to the selection bias and potential loss of accuracy inherent in this approach. Data collection required a small degree of subjectivity, particularly in etiologic classifications and attribution of comorbidities. While our 30-day mortality data provides selective validation to previously reported data in both the private and Veterans Administration sector, identified risk factors for prolonged LOS require externally validation, as the generalizability of our cohort may be limited.26 Finally, endpoints such as wound complications, major adverse cardiac events and other major morbidities were not considered in this analysis, and these factors may be of paramount importance in both assessing the potential futility of an AKA or providing appropriate prognostic information to patients and families. Furthermore, it would be valuable to extend our mortality rates to one, two or five years out, with a concomitant validated measure of functional status or quality of life as well.

Suggestion of non-operative management due to a high risk of mortality is difficult, and guided primarily by the clinician’s judgment. Understanding the aspects of the clinical profile of a pre-operative patient unlikely to survive to discharge provides an evidence-based adjunct to assist the surgeon in providing the patient and family the appropriate context to make the best clinical decision. Additionally, our findings may optimize prognostic guidance in providing realistic expectations about the time until discharge, particularly with respect to burn patients who required an AKA.

CONCLUSIONS

The AKA is a highly morbid procedure, one in which outcomes data severely lacks in contrast to other common vascular operations. In this study, we validated several important risk factors for 30-day mortality after AKA, and provided new insight into risk factors portending a prolonged LOS as well. Despite limitations, these data allow for the improved pre-operative stratification of AKA patients, and subsequently may allow for more informed decision making and improved anticipation of a pending post-operative course.

Acknowledgments

FUNDING

Grant Support Acknowledgement:

Vanderbilt RedCAP: CTSA Award UL1 TR000445 from NCATS/NIH

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

CONFLICTS OF INTEREST

None

REFERENCES

  • 1.Sandnes DK, Sobel M, Flum DR. Survival after lower-extremity amputation. J Am Coll Surg. 2004;199(3):394–402. doi: 10.1016/j.jamcollsurg.2004.05.270. [DOI] [PubMed] [Google Scholar]
  • 2.Dillingham TR, Pezzin LE, MacKenzie EJ. Limb amputation and limb deficiency: epidemiology and recent trends in the United States. South Med J. 2002;95(8):875–83. doi: 10.1097/00007611-200208000-00018. [DOI] [PubMed] [Google Scholar]
  • 3.Nehler MR, Hiatt WR, Taylor LM., Jr. Is revascularization and limb salvage always the best treatment for critical limb ischemia? J Vasc Surg. 2003;37(3):704–8. doi: 10.1067/mva.2003.142. [DOI] [PubMed] [Google Scholar]
  • 4.Ploeg AJ, Lardenoye JW, Vrancken Peeters MP, et al. Contemporary series of morbidity and mortality after lower limb amputation. Eur J Vasc Endovasc Surg. 2005;29(6):633–7. doi: 10.1016/j.ejvs.2005.02.014. [DOI] [PubMed] [Google Scholar]
  • 5.Nehler MR, Coll JR, Hiatt WR, et al. Functional outcome in a contemporary series of major lower extremity amputations. J Vasc Surg. 2003;38(1):7–14. doi: 10.1016/s0741-5214(03)00092-2. [DOI] [PubMed] [Google Scholar]
  • 6.Suckow BD, Goodney PP, Cambria RA, et al. Predicting functional status following amputation after lower extremity bypass. Ann Vasc Surg. 2012;26(1):67–78. doi: 10.1016/j.avsg.2011.07.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Cruz CP, Eidt JF, Capps C, et al. Major lower extremity amputations at a Veterans Affairs hospital. Am J Surg. 2003;186(5):449–54. doi: 10.1016/j.amjsurg.2003.07.027. [DOI] [PubMed] [Google Scholar]
  • 8.Faglia E, Clerici G, Caminiti M, et al. Mortality after major amputation in diabetic patients with critical limb ischemia who did and did not undergo previous peripheral revascularization Data of a cohort study of 564 consecutive diabetic patients. J Diabetes Complications. 2010;24(4):265–9. doi: 10.1016/j.jdiacomp.2009.02.004. [DOI] [PubMed] [Google Scholar]
  • 9.Nelson MT, Greenblatt DY, Soma G, et al. Preoperative factors predict mortality after major lower-extremity amputation. Surgery. 2012;152(4):685–94. doi: 10.1016/j.surg.2012.07.017. discussion 694-6. [DOI] [PubMed] [Google Scholar]
  • 10.Karam J, Shepard A, Rubinfeld I. Predictors of operative mortality following major lower extremity amputations using the National Surgical Quality Improvement Program public use data. J Vasc Surg. 2013;58(5):1276–82. doi: 10.1016/j.jvs.2013.05.026. [DOI] [PubMed] [Google Scholar]
  • 11.Malone M, Lau NS, White J, et al. The effect of diabetes mellitus on costs and length of stay in patients with peripheral arterial disease undergoing vascular surgery. Eur J Vasc Endovasc Surg. 2014;48(4):447–51. doi: 10.1016/j.ejvs.2014.07.001. [DOI] [PubMed] [Google Scholar]
  • 12.Roden DM, Pulley JM, Basford MA, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther. 2008;84(3):362–9. doi: 10.1038/clpt.2008.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Zayed M, Bech F, Hernandez-Boussard T. National review of factors influencing disparities and types of major lower extremity amputations. Ann Vasc Surg. 2014;28(5):1157–65. doi: 10.1016/j.avsg.2013.11.008. [DOI] [PubMed] [Google Scholar]
  • 14.Wise ES, Ladner TR, Song J, et al. Race as a predictor of delay from diagnosis to endarterectomy in clinically significant carotid stenosis. Journal of Vascular Surgery. 2015:61. doi: 10.1016/j.jvs.2015.01.057. In Press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. doi: 10.1016/j.jbi.2008.08.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Fortington LV, Geertzen JH, van Netten JJ, et al. Short and long term mortality rates after a lower limb amputation. Eur J Vasc Endovasc Surg. 2013;46(1):124–31. doi: 10.1016/j.ejvs.2013.03.024. [DOI] [PubMed] [Google Scholar]
  • 17.Stone PA, Flaherty SK, Aburahma AF, et al. Factors affecting perioperative mortality and wound-related complications following major lower extremity amputations. Ann Vasc Surg. 2006;20(2):209–16. doi: 10.1007/s10016-006-9009-z. [DOI] [PubMed] [Google Scholar]
  • 18.Rosen N, Gigi R, Haim A, et al. Mortality and reoperations following lower limb amputations. Isr Med Assoc J. 2014;16(2):83–7. [PubMed] [Google Scholar]
  • 19.Reed AB, Delvecchio C, Giglia JS. Major lower extremity amputation after multiple revascularizations: was it worth it? Ann Vasc Surg. 2008;22(3):335–40. doi: 10.1016/j.avsg.2007.07.039. [DOI] [PubMed] [Google Scholar]
  • 20.Brewer P, Riddell Z, Grimer RJ, et al. Perioperative mortality following above-knee amputations indicated for bone and soft tissue tumours. Eur J Surg Oncol. 2012;38(8):706–10. doi: 10.1016/j.ejso.2012.03.004. [DOI] [PubMed] [Google Scholar]
  • 21.Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10(4):222. doi: 10.1186/cc4975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Vanderschueren S, De Weerdt A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med. 2000;28(6):1871–6. doi: 10.1097/00003246-200006000-00031. [DOI] [PubMed] [Google Scholar]
  • 23.O'Brien PJ, Cox MW, Shortell CK, et al. Risk factors for early failure of surgical amputations: an analysis of 8,878 isolated lower extremity amputation procedures. J Am Coll Surg. 2013;216(4):836–42. doi: 10.1016/j.jamcollsurg.2012.12.041. discussion 842-4. [DOI] [PubMed] [Google Scholar]
  • 24.Feinglass J, Pearce WH, Martin GJ, et al. Postoperative and late survival outcomes after major amputation: findings from the Department of Veterans Affairs National Surgical Quality Improvement Program. Surgery. 2001;130(1):21–9. doi: 10.1067/msy.2001.115359. [DOI] [PubMed] [Google Scholar]
  • 25.Mullen JL, Gertner MH, Buzby GP, et al. Implications of malnutrition in the surgical patient. Arch Surg. 1979;114(2):121–5. doi: 10.1001/archsurg.1979.01370260011001. [DOI] [PubMed] [Google Scholar]
  • 26.Vogel TR, Petroski GF, Kruse RL. Impact of amputation level and comorbidities on functional status of nursing home residents after lower extremity amputation. J Vasc Surg. 2014;59(5):1323–30. doi: 10.1016/j.jvs.2013.11.076. e1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Ambler GK, Brooks DE, Al Zuhir N, et al. Effect of frailty on short- and mid-term outcomes in vascular surgical patients. Br J Surg. 2015 doi: 10.1002/bjs.9785. [DOI] [PubMed] [Google Scholar]
  • 28.Visser L, Prent A, van der Laan MJ, et al. Predicting postoperative delirium after vascular surgical procedures. J Vasc Surg. 2015 doi: 10.1016/j.jvs.2015.01.041. [DOI] [PubMed] [Google Scholar]
  • 29.Curran T, Zhang JQ, Lo RC, et al. Risk factors and indications for readmission after lower extremity amputation in the American College of Surgeons National Surgical Quality Improvement Program. J Vasc Surg. 2014;60(5):1315–24. doi: 10.1016/j.jvs.2014.05.050. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES